Latest | Instant Finance & Market News_第103页 | NewTimeSpace

08:59

[ SBP GROUP (01177.HK): Kylo-11 Phase I data published in The Lancet; single dose reduces Lp(a) by up to 97% at week 48 ] NewTimeSpace News: On 31 August 2026, SBP GROUP (01177.HK) announced that the final Phase I data of Kylo-11 (LPA siRNA), a Class 1 innovative drug developed by its wholly-owned subsidiary Hejiya Biomedical, were presented at ESC 2026 as an LBCT oral presentation and published in full in The Lancet; among 70 subjects, a single dose significantly and durably reduced Lp(a), with mid-to-high dose groups achieving reductions of 94.6%-97.0% at week 48, approaching maximum reduction within about 4 weeks in the 225 mg and above groups and maintained through week 48, supporting the "once-a-year" dosing strategy; no serious adverse events occurred and tolerability was generally good; a Phase II study is underway in China and the US.

Tag： SBP GROUP 01177.HK Clinical Progress

08:57

[ HUTCHMED (00013.HK): SANOVO Phase III of ORPATHYS plus TAGRISSO meets primary endpoint in first-line EGFR-mutant NSCLC, with significant PFS benefit ] NewTimeSpace News: On 31 August 2026, HUTCHMED (00013.HK) announced that the SANOVO Phase III study in China of ORPATHYS plus TAGRISSO in treatment-naive EGFR-mutant NSCLC with MET overexpression met its primary endpoint, demonstrating a statistically significant and highly clinically meaningful PFS improvement in both the high-MET and ITT populations, with encouraging OS benefit; the study enrolled 326 patients (NCT05009836), with a safety profile consistent with known profiles; the combination is already approved in China for previously treated patients based on SACHI, and the SAFFRON global Phase III also reported positive data in August 2026.

Tag： HUTCHMED 00013.HK Clinical Trial

08:54

[ Novlead Biotech files re-application with HKEX; core product iNOwill certified in China and EU, with five approved products spanning cardiopulmonary care scenarios ] NewTimeSpace News: On 28 August 2026, Nanjing Novlead Biotechnology Co., Ltd. re-filed its listing application with HKEX; incorporated in 2018, the Company focuses on inhaled nitric oxide (iNO) therapy, with five approved products (including core product iNOwill, approved by the NMPA in 2022 and CE-certified in 2025) and five candidates in development covering critical care, ward, outpatient and home scenarios; its R&D team of 47 employees represents about 27.5% of total headcount, with H1 2026 R&D expenses of approximately RMB 20.3 million; production facilities are located in Yangzhou, Jiangsu and Fangchenggang, Guangxi.

Tag： Novlead Biotech IPO file a listing application

08:42

[ Chint Electrics files for HKEX listing; world's largest residential PV installer by cumulative capacity and China's largest low-voltage electrical products maker ] NewTimeSpace News: On 28 August 2026, Zhejiang Chint Electrics Co., Ltd. filed a listing application with HKEX, with CICC, Huatai International and Guotai Junan International as joint sponsors; the Company is a globally leading power and integrated energy solutions provider with two segments — smart electrical products and green energy solutions; as of 30 June 2026 it operates six production bases and nearly 400 distributors in China covering 265 prefecture-level cities, serving over 50 countries and regions overseas; the Company ranks fifth globally and second in China in low-voltage electrical products (largest in China), and ranks first globally in residential PV with cumulative installations of 58.0 GW (12.8% market share).

Tag： Chint Electrics IPO file a listing application

08:38

[ Capchem files updated prospectus with HKEX; electronics chemicals and functional materials provider with CITIC Securities and CICC as joint sponsors ] NewTimeSpace News: On 28 August 2026, Shenzhen Capchem Technology Co., Ltd. filed an updated prospectus with HKEX, with CITIC Securities and CICC as joint sponsors; the Company is a China-headquartered provider of electronic chemicals and functional materials with three business segments — battery chemicals, organic fluorochemicals and electronic information chemicals — serving industries including NEV, energy storage, consumer electronics, AI and digital infrastructure and semiconductor manufacturing, with 13 production bases; founded in 2002 with its predecessor dating to 1996, the Company primarily adopts a direct sales model, with direct sales accounting for approximately 90% of revenue in recent periods.

Tag： Capchem IPO file a listing application

08:34

[ VivaVision Biotech files for HKEX listing with CICC as sole sponsor; both core ophthalmic products in Phase III trials ] NewTimeSpace News: On 28 August 2026, VivaVision Biotech (Zhejiang) Co., Ltd. filed a listing application with HKEX, with CICC as sole sponsor; founded in 2016, the Company is a clinical-stage biotech company focused on ophthalmology, with two core products — VVN461 (high dose), a JAK1/TYK2 dual-target inhibitor for non-infectious anterior uveitis, and VVN001, a second-generation LFA-1 antagonist for moderate-to-severe dry eye disease — both in Phase III trials in China, plus three other clinical-stage candidates; the Company has no approved drugs and its commercialization will rely primarily on collaboration with well-known pharmaceutical companies.

Tag： VivaVision IPO file a listing application

08:25

[ Excelland Robotics (03231.HK): Launches global offering at maximum offer price of HKD 19.55, expected to list on 9 September ] NewTimeSpace News: On 31 August 2026, Excelland Robotics (03231.HK) announced a global offering of 45,000,000 H shares at an offer price range of HKD 14.45-19.55 per share, with 200 shares per board lot and an entry fee of approximately HKD 3,949.44; the Hong Kong public offering runs from 9:00 a.m. on 31 August to 12:00 noon on 4 September, with expected pricing on 7 September, results by 8 September and listing on 9 September; based on a mid-point offer price of HKD 17.00, 2 cornerstone investors (SensePower and CYGG) have subscribed for approximately 1,389,200 shares in aggregate, representing approximately 3.09% of the offer shares and approximately 0.33% of the issued share capital; the Company is applying for a listing under Chapter 18C of the Listing Rules.

Tag： Excelland Robotics 03231.HK IPO Global Offering

08:01

[ Longsys (09976.HK): Global offering of 26.0778 million H shares at maximum offer price of HKD 240.60, expected to list on 8 September ] NewTimeSpace News: On 31 August 2026, Longsys (09976.HK) announced a global offering of 26,077,800 H shares at a maximum offer price of HKD 240.60 per share, with 50 shares per board lot and an entry fee of approximately HKD 12,151.32; the Hong Kong public offering runs from 9:00 a.m. on 31 August to 12:00 noon on 3 September, with expected pricing on 4 September, the final offer price and application results to be announced by 7 September, and the H shares expected to commence trading on 8 September; a total of 15 cornerstone investors have been introduced with an aggregate subscription of approximately 4,926,050 shares, representing approximately 18.89% of the total offer shares; the stabilising manager is CLSA Limited, with the stabilising period ending on 3 October 2026.

Tag： LONGSYS 09976.HK IPO Global Offering

08:01

[ RIVERINE CHINA (01417.HK): Plans to establish new AI infrastructure business building an AI Token Economy system ] NewTimeSpace News: On 31 August 2026, RIVERINE CHINA (01417.HK) announced that the Board has resolved, while continuing to develop its existing property management/building leasing/catering/sanitation businesses, to establish a new AI infrastructure business and gradually build an AI Token Economy system centered on AI Token production and distribution; the Group has established TokenVerse Holdings Limited (intermediate holding company) and the domestic entity Shanghai Ciyuan Wanxiang Information Technology Co., Ltd.; the announcement clarified that AI Token is only a service measurement unit, not any currency or virtual asset, and the AI Token Economy does not involve the issuance of virtual currency or digital assets.

Tag： RIVERINE CHINA 01417.HK Business Expansion Token

23:07

[ HK Sub-New-Listings Tracking Weekly: DEEPZERO Cumulative Gain of 1,320% Tops the List; AUX ELECTRIC to Unlock 1.301 Billion Shares Next Week - 20260828 ] This week, Hong Kong sub-new-listings ended mixed, with HIPINE up 30.55% to lead gains, while B&K CORP-B, after surging 68% last week, retreated 25.55%. JIAXIN INTL RES fell 4.87% for the week after unlocking 280 million shares, and SHUANGDENG fell 7.36%, with the impact mild. DEEPZERO's cumulative gain of 1,320% overtook QIYUNSHAN FOOD to top the list, while CIDI's discount widened to 93.12%. Z.AI's average daily turnover fell to HKD 4.672 billion, the lowest since July. Next week, AUX ELECTRIC will unlock 1.301 billion shares, a notably large size.

Tag： HK Sub-New-Listings Tracking Weekly HIPINE JIANGXI BIO

22:29

[ HK Stock Connect Weekly Report: HSI Falls 1.63% for the Week, Alibaba's HKD 80 Billion Placement Fully Committed to AI, ZJ INNOLIGHT Officially Added to Stock Connect ] NewTimeSpace News: The HSI fell 1.63% this week, the Hang Seng TECH Index fell 3.38% and the Hang Seng China Enterprises Index fell 1.67%, with southbound capital posting a net inflow of approximately HKD 15.8 billion for the week. Alibaba announced an HKD 80 billion placement with 100% of proceeds directed to AI infrastructure, and its shares fell about 7.5% for the week, while Jack Ma and management made combined purchases exceeding HKD 800 million. The HSI quarterly review continued to resonate, with 54 stocks expected to enter Stock Connect on 7 September and an estimated HKD 38.6 billion of flows; DIAGENS-B and STAR SPORTS MED led gains, and ZJ INNOLIGHT was officially added to Stock Connect. The CRO/innovative drug complex was strong first and weak later, with EVEREST MED up over 18% on Tuesday; TIANQI LITHIUM's interim net profit surged 49 times. SHEIN-W completed its offering for a 1 September listing, and Medcaptain Medical Technology launched its offering.

Tag： HK Stock Connect Weekly Report Alibaba-W Tencent XIAOMI-W

21:28

[ CHINA BAOLI TEC (00164.HK): Proposes to allot 132.68 million new shares for proceeds of about HKD 63.82 million under specific mandate ] NewTimeSpace News: On 28 August 2026 (after trading hours), CHINA BAOLI TEC (00164.HK) announced that it has entered into subscription agreements with 20 subscribers to allot 132,682,600 new shares at HKD 0.481 per share (representing about 38.00% of existing issued shares), for gross proceeds of approximately HKD 63.82 million and net proceeds of approximately HKD 60.3 million; the proceeds are intended for working capital, the converged media business and the dry-grinding and dry-separation business of the Mongolian mining project; the subscription requires shareholders' approval of a specific mandate at the EGM, with 11 subscribers holding existing interests required to abstain from voting.

Tag： CHINA BAOLI TEC 00164.HK Share issuance

21:23

[ ZCZL (00564.HK): Obtains bank commitment letter for share buyback special loan of up to RMB 360 million ] NewTimeSpace News: On 30 August 2026, ZCZL (00564.HK) announced that it has obtained a share buyback special loan commitment letter from the Zhengzhou Branch of China CITIC Bank, with a committed amount of no more than RMB 360.00 million and a term of no more than 36 months for the exclusive purpose of repurchasing A shares; the Company's repurchase plan involves total funds of RMB 300-400 million (part for cancellation and part for equity incentives/employee shareholding plans), approved by the Board and shareholders' meetings, with specific terms subject to the loan contract and repurchase implementation results.

Tag： ZCZL 00564.HK Share Buyback

21:21

[ LIAONING PORT (02880.HK): Applies to DCE for iron ore designated delivery warehouse and bonded delivery warehouse qualifications ] NewTimeSpace News: On 28 August 2026, LIAONING PORT (02880.HK) announced plans to apply to the DCE for both designated iron ore duty-paid and bonded delivery warehouse qualifications, operated by its Dalian Port Bulk Cargo Terminal Branch under a dual-track delivery model; a previously 40%-owned joint venture had its delivery business suspended in January 2026 for failing to meet net asset requirements, while this application is made by the Company itself; the matter has been approved by the Board and does not require shareholders' approval, though the qualification approval remains subject to uncertainty.

Tag： LIAONING PORT 02880.HK Business Expansion

21:18

[ SHENGRONG HLDG (00834.HK): Proposes voluntary delisting of shares from SGX Mainboard, expected to take effect on or around 7 January 2027 ] NewTimeSpace News: On 30 August 2026, SHENGRONG HLDG (00834.HK) announced its proposal to voluntarily delist its secondarily listed shares from the SGX Mainboard, expected to take effect on or around 7 January 2027; the reasons include negligible share registration and low trading volume on SGX, no fund-raising since 2007 and streamlined compliance costs; as the primary listing is on HKEX, no shareholders' approval is required; SGX indicated no objection on 28 August 2026, notices will be despatched on or around 5 October 2026, and the shares will trade only on HKEX after delisting.

Tag： SHENGRONG HLDG 00834.HK Delisting

20:54

[ XINXIN MINING (03833.HK): Strategic restructuring of controlling shareholder approved by Xinjiang regional government; no change of control involved ] NewTimeSpace News: On 28 August 2026, XINXIN MINING (03833.HK) announced that the strategic restructuring between controlling shareholders Xinjiang Nonferrous and Xinjiang Geology & Minerals has been approved by the People's Government of the Xinjiang Uygur Autonomous Region; the restructuring does not involve major asset restructuring of the Company, any change of controlling shareholder or actual controller, or any material impact on operations, though implementation remains subject to uncertainties.

Tag： XINXIN MINING 03833.HK strategic restructuring

20:53

[ ASCLETIS-B (01672.HK): First subject dosed in global Phase III program of oral GLP-1 agonist ASC30 for long-term weight management, targeting ~4,600 subjects ] NewTimeSpace News: On 30 August 2026, ASCLETIS-B (01672.HK) announced that the first subject has been dosed in the global Phase III program (AURORA-1/AURORA-2, ~4,600 subjects) of once-daily oral small-molecule GLP-1 receptor agonist ASC30 for long-term weight management; topline data are expected in Q3 2028, with an NDA to the US FDA by end-2028 and an MAA to the EMA in early 2029, and if approved ASC30 could become the second oral small-molecule GLP-1 agonist launched in the US and Europe; the pipeline also includes GLP-1/GIP dual-target and triple-target fixed-dose combinations.

Tag： ASCLETIS-B 01672.HK Clinical Trial

20:49

[ FOSUN INTL (00656.HK): Proposes spin-off and separate listing of Club Med Lifestyle on HKEX Main Board; listing application submitted ] NewTimeSpace News: On 28 August 2026, FOSUN INTL (00656.HK) announced that HKEX has confirmed the Company may proceed with the spin-off of its subsidiary Club Med Lifestyle (Mediterranean resort group) for a separate listing on the Main Board under Practice Note 15, with Club Med Lifestyle submitting a listing application through its joint sponsors on the same day; Club Med Lifestyle will remain a subsidiary after the proposed offering and existing shareholders will receive a guaranteed entitlement; the proposed spin-off is expected to constitute a possible discloseable transaction (percentage ratios expected to exceed 5% but below 25%), subject to Listing Committee approval.

Tag： FOSUN INTL 00656.HK Separate Listing

20:46

[ SANY HEAVY IND (06031.HK): Plans asset-backed special plan and ABS issuance of up to RMB 10 billion; controlling shareholder to subscribe all subordinated tranche ] NewTimeSpace News: On 28 August 2026, SANY HEAVY IND (06031.HK) announced plans to establish an asset-backed special plan and register the issuance of finance lease ABS with an aggregate principal of no more than RMB 10 billion, listed on the SSE with each tranche lasting no more than 5 years; controlling shareholder SANY Group will subscribe for all subordinated ABS (up to RMB 1 billion in aggregate), with the Company acting as liquidity shortfall payment undertaker; the transaction constitutes a connected transaction subject to shareholders' meeting approval, with connected directors having abstained from voting.

Tag： SANY HEAVY IND 06031.HK ABS

20:43

[ GCL TECH (03800.HK): Leshan 200,000-tonne LFP project in production; silicon-carbon anode pilot project also launched ] NewTimeSpace News: On 28 August 2026, GCL TECH (03800.HK) announced that the first phase of the 200,000-tonne LFP cathode material project in Leshan commenced production in June 2026, adopting the world's first iron-red process GCL-PHY one-step technology, with full production expected by end-October and a second phase of 200,000 tonnes expected by end-Q1 2027; a 10,000-tonne-scale silicon-carbon anode pilot project has commenced production in Xuzhou, and as the world's largest silane producer the Group plans to build the world's largest silicon-carbon anode base in Leshan; the announcement cautions on five categories of risks.

Tag： GCL TECH 03800.HK Business Expansion

Scan QR Code

Download App